Chi Ching Mak

Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera

Gerlinde Wernig, Michael G. Kharas, Rachel Okabe et al. · Cancer Cell · 2008 · 380 citations · Full text

Medicine, Jak2v617f-induced Polycythemia Vera, Murine Model +8

TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations

Animesh Pardanani, John Hood, Terra L. Lasho et al. · Leukemia · 2007 · 281 citations

Hematological Malignancy, Receptor Tyrosine Kinase, Myeloproliferative Disorder-associated Jak2v617f +8

Directed evolution of D-2-keto-3-deoxy-6-phosphogluconate aldolase to new variants for the efficient synthesis of D- and L-sugars

Sun Fong, Timothy Machajewski, Chi Ching Mak et al. · Chemistry & Biology · 2000 · 154 citations · Full text

Biosynthesis, Engineering, Aldo-keto Reductase +11

The CLK inhibitor SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression in gastrointestinal cancer models

Betty Y. Tam, Kevin Chiu, Heekyung Chung et al. · Cancer Letters · 2019 · 139 citations · Full text

Clk Inhibitor Sm08502, Wnt Pathway Genes, Pathology +19

Selective Inhibition of JAK2-Driven Erythroid Differentiation of Polycythemia Vera Progenitors

Ifat Geron, Annelie Abrahamsson, Charlene F. Barroga et al. · Cancer Cell · 2008 · 134 citations · Full text

Developmental Biology, Cell Regulation, Receptor Tyrosine Kinase +10